Polycerasoidol, a Natural Prenylated Benzopyran with a Dual PPAR alpha/PPAR gamma Agonist Activity and Anti-inflammatory Effect

Fecha de publicación: Fecha Ahead of Print:

Autores de INCLIVA

Participantes ajenos a INCLIVA

  • Bermejo, A
  • Collado, A
  • Barrachina, I
  • El Aouad, N
  • Franck, X
  • Garibotto, F
  • Dacquet, C
  • Caignard, DH
  • Suvire, FD
  • Enriz, RD
  • Figadere, B
  • Cortes, D

Grupos y Plataformas de I+D+i

Abstract

Dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR alpha/gamma) agonists regulate both lipid and glucose homeostasis under different metabolic conditions and can exert anti-inflammatory activity. We investigated the potential dual PPAR alpha/gamma agonism of prenylated benzopyrans polycerasoidol (1) and polycerasoidin (2) and their derivatives for novel drug development. Nine semisynthetic derivatives were prepared from the natural polycerasoidol (1) and polycerasoidin (2), which were evaluated for PPAR alpha/gamma, -delta and retinoid X receptor-alpha activity in transactivation assays. Polycerasoidol (1) exhibited potent dual PPAR alpha/gamma agonism and low cytotoxicity. Structure activity relationship studies revealed that a free phenol group at C-6 and a carboxylic acid at C-9' were key features for dual PPAR alpha/gamma agonism activity. Molecular modeling indicated the relevance of these groups for optimal ligand binding to the PPAR alpha and PPAR gamma domains. In addition, polycerasoidol (1) exhibited a potent anti-inflammatory effect by inhibiting mononuclear leukocyte adhesion to the dysfunctional endothelium in a concentration-dependent manner via RXR alpha/PPAR gamma interactions. Therefore, polycerasoidol (1) can be considered a hit-to-lead molecule for the further development of novel dual PPAR alpha/gamma agonists capable of preventing cardiovascular events associated with metabolic disorders.

© 2019 American Chemical Society and American Society of Pharmacognosy

Datos de la publicación

ISSN/ISSNe:
0163-3864, 1520-6025

JOURNAL OF NATURAL PRODUCTS  American Chemical Society

Tipo:
Article
Páginas:
1802-1812
PubMed:
31268307

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Financiación

Proyectos y Estudios Clínicos

Estudio de nuevos mecanismos inflamatorios y angiogénicos asociados a la obesidad grave morbida: papel del eje CXCR3 y los receptores RORs.

Investigador Principal: LAURA PIQUERAS RUIZ

PI15/00082 . INSTITUTO SALUD CARLOS III . 2016

A multidisciplinary project to advance in basic mechanisms, diagnosis, prediction, and prevention of cardiac damage in reperfused acute myocardial infarction.

Investigador Principal: VICENT BODÍ PERIS

PIE15/00013 . INSTITUTO SALUD CARLOS III . 2016

Modulación inmunofarmacológica de la inflamación sistémica asociada a desórdenes metabólicos. Búsqueda de nuevas dianas terapéuticas y síntesis de fármacos novedosos.

Investigador Principal: MARIA JESUS SANZ FERRANDO

SAF2014-57845-R . MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2015

Synthesis and pharmacological evaluation of new dual PPARalpha/gamma agonists as new therapeutic tools in the control of cardiometabolic disorders

Investigador Principal: NURIA CABEDO ESCRIG

CP15/00150 . INSTITUTO SALUD CARLOS III . 2016

RETOS 2017. MODULACION FARMACOLOGICA DEL SISTEMA INMUNE COMO DIANA CLAVE EN LA PREVENCION DE LA ENFERMEDAD CARDIOVASCULAR ASOCIADA A DESORDENES METABOLICOS. SINTESIS DE FARMACOS NOVEDOSOS

Investigador Principal: MARIA JESUS SANZ FERRANDO

SAF2017-89714-R . MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2018

Desarrollo quimico y farmacologico de nuevos farmacos "multidiana" en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular asociada

Investigador Principal: NURIA CABEDO ESCRIG

PI18/01450 . INSTITUTO SALUD CARLOS III . 2019

Cita

Compartir